The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
So fidelity have taken a 5% plus stake in SRC.very interesting.
Well at least some activity at DLI
https://twitter.com/Deep_Longevity/status/1781211957413986356?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
nothing very significant of course,but at least some sign of life.
massively disappointing that no confirmation yet of chinese NDA submission.what is the problem with these people. so unprofessional!
The packaging looks very impressive to me. i can see this being extremely popular.
Personally i'm surprised that it is still legal to sell bananas.! only a matter if time i expect.lol
Morning bignose.well that is an interesting take on things.i certainly hope your interpretation is correct.fingers crossed as always.do you think Apple would have had the same degree of success is they had been called "Banana"? hey guys, come and see my new Banana, doesn't seem to have quite the right ring to it.lol
Completely agree,panda1.
No problemo.
Morning bignose. yes difficult to understand how impurities was allowed to remain an issue for so long. anyway, issue now is can they actually sell enough cans to provide some form of tangible income. 30k to 416 k seems an unrealistic step up unless there is some very significant and previously unrecognised demand,which does,i'm afraid,seem very unlikely..
Thanks for the further info bignose.does seem a tad odd to be saying basically we have no say in the manufacturing process etc. one might have expected some degree of mutuality in the rights and obligations under the licence agreement which would give regent some say over things.i suppose when you are in such a weak position as regent is, having enforceable rights on paper may simply be an academic point in practice (no alternative).sorry im just chuntering i know.
Morning bignose. yes i imagine royalty finance is like that.you take a percentage of ultimate royalties etc,which could impact future earnings dramatically. all speculation of course and i suppose the other side of the coin is that mellon has considerable resources at his disposal,so not in the same desperate situation which some companies are in when they resort to damaging finance options. anyway time will tell.on the clinical holds point,i agree that a potential finance provider would certainly want the reassurance of a formal SPA before proceeding.i probably didn't express myself clearly,as i was just wondering if the no holds statement indicated any real progress with the fda and was not suggesting regent might go ahead without one. lets hope for NDA submission news without further delay.
Sorry, lanstead, not lansdown.memory not what it was.
Cont. as to royalty financing,my ears did prick up on hearing this. whilst i'm familiar with a lot of last resort financing (e.g. convertible loan notes of the death spiral variety, such as specialised in by companies like lansdown), im not familiar with royalty financing as such. i assume,on the principle that no one does anything for free, this would come at a very considerable cost in terms of regent's potential profitability, even if it is not in strict terms,dilutive.i f anyone is familiar with this type of finance and has experienced it in practice i would be interested to hear their thoughts. of course,anything (within reason) which enables regent to carry on and leaves at least a little on the table for its PIs is better that going bust, but i do have concerns as to the road regent may have to go down in that regard.
well that's more than enough from me.gla
I mentioned earlier the there were 2 or 3 particular points in the response which caught my attention.first it was good to see the identity of the manufacturer.second,the figures given re manufacturing capability seem to be of a different order from what we have been told in the past.i sense you feel likewise and are somewhat sceptical of this,a sensible approach bearing in mind how often Regent 's statements have had only a passing acquaintance with accuracy.
the main points however, were their statement about no clinical holds and the reference to royalty financing. does the reference to "no clinical holds"mean that they could in principle (certainly not in practice proceed with a trial ,but without the benefit of a formal SPA?.my understanding,which may well be inaccurate, is that an SPA is not essential for a trial to take place,but the risk is much greater as there would have been no formal agreement with the fda on the criteria and format etc of such trial. having a formal spa in place is, equally, no guarantee of the trial drug being approved, even if the results meet the endpoints specified in the protocol, as the fda will still want to assess the trial results on the basis of their normal criteria. so,having no clinical holds does not mean we have any substantive form of go-ahead, but it does perhaps indicate that the discussions so far with the FDA have achieved some degree of tangible progress. just my musings of course. tbc
Its!
Articles are two a penny.https://finance.yahoo.com/news/heres-why-were-not-concerned-064340814.html i haven't read the full mail article,but from the extract quoted,it's stance appears very much at odds withe the general interpretation of the results.
Morning bignose.no i hadn't seen it,so thanks very much for that. interesting that mellon through galloway is prepared to extend a further loan.small beer to him of course,but presumably indicates he can still see some light t the end of the tunnel.i agree it's prudent to be sceptical about any rerate in view of the history here, but i suppose it is possible. q1 is now over and no news on submission,but as you say could be any time.
kudos to you again for pursuing a direct approach to the board and eliciting the response posted yesterday. tbh, i had completely given up on a direct approach in light of the wall of silence which seemed to prevail.very glad you have proved me wrong.
there were 2 or 3 nuggets of information in their reply,which i will comment on later, hopefully.
Completely agree,weareallguessing. i also topped up this afternoon when the s/p appeared to have stabilised.when you consider the likely news flow over the next 12 months or so,it is very hard to imagine the s/p staying at this low level for long.aimo.
Bignose,thanks very much for the detailed post.much appreciated. need to look at it in detail later.
Afternoon bignose.agree with that.i haven't bothered to calculate the value of a 10k trade but it is less than £1000 think.these anomalous rises and falls on derisory volume don't mean anything imo.still t least it was a rise.
I ss we have a trading statement on the 12th, presumably ahead of the agm.